Zealand Pharma's senior vice president Arvind Hundal steps down
Denmark-based biotech company Zealand Pharma (Nasdaq Copenhagen: ZEAL) announced today that senior vice president and chief business officer, Arvind Hundal, has stepped down to pursue other opportunities outside the company.
Arvind Hundal joined Zealand in 2009 and was nominated to the position of Chief Business Officer in 2011, at which time she also joined the company’s Executive Management team.
David Solomon, president and chief executive of Zealand, said: “Arvind Hundal has made valuable contributions to building Zealand’s large portfolio of partnership agreements over the past five years. It is to a large extent also thanks to Arvind and the team’s achievements that Zealand today stands with a solid platform from which to move to the next level in its development, and we wish her all the best in her next endeavors.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze